Remove tag access-clinical-trials
article thumbnail

Benefits of blockchain in limiting counterfeit drug distribution

European Pharmaceutical Review

A benefit of blockchain in the pharmaceutical supply chain is its compatibility with other technologies such as radio frequency identification (RFID) and barcodes, plus its accessibility throughout the supply chain in real time. Blockchain offers the possibility of non-modifiable data uploading with traceability and low-cost data storage.

article thumbnail

Free access to Zolgensma curbed, says Novartis

pharmaphorum

Novartis’ programme providing free access to its spinal muscular atrophy (SMA) gene therapy Zolgensma is being scaled back to a dozen countries worldwide, according to the company. ” Zolgensma is one of the most expensive therapies available, with a price tag of around $2.1 Pause in UK access.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

What Tech Trends Do Life Sciences Marketers Need to Know About?

PM360

Another capability made possible by fine-tuning is the enhancement of content tagging. Content tagging has always been a labor-intensive task. Auto-tagging ensures that the right content efficiently reaches the right customers. Fine-tuning models can target domains and generate prompts to tag the content into relevant topics.

article thumbnail

Rare Disease Spotlight – tracing the rise of orphan drug designations over almost 40 years

Pharmaceutical Technology

The US Food and Drug Administration (FDA) put a high-profile bluebird bio trial for sickle cell disease on partial clinical hold, and advisory panels deliberated over decisions involving gene therapies for amyotrophic lateral sclerosis (ALS), cerebral adrenoleukodystrophy (CALD), and beta-thalassemia.

article thumbnail

A broad range of unmet needs remains in the immuno-oncology space

Pharmaceutical Technology

IO therapies come with a hefty price tag, with ICI therapies in the US typically exceeding $100,000, while cell therapies can exceed $400,000. There is currently a rich and diverse IO pipeline that aims to address these unmet needs, with 703 IO products currently in clinical trials. Cost-related unmet needs also scored highly.

article thumbnail

Pioneering the Path Pre- and Post-Launch Strategies

PM360

From defining the target product profile to shaping clinical endpoints and devising asset strategies to crafting scientific narratives, the value of Medical Affairs permeates every aspect of product development. Today, teams are indispensable strategic partners, deeply involved in crafting the very foundation of a product’s journey.

Medical 52
article thumbnail

Q&A: A decade on, what’s next for CAR-T therapies?

Pharmaceutical Technology

But access to these treatments continues to remain limited due to high price tags and variable availability across regions. And my estimate is that between 25,000 and 30,000 patients have been treated with those therapies globally, which does not include patients treated in clinical trials.